Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

Conditions

• Arthroplasty

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Oral Tranexamic Acid — DRUG
  Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3

Study Details

The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Key Dates

First listed

Feb 18, 2025

Start date

Jun 1, 2026

Status verified

Jul 2026

Primary completion

Jun 30, 2027

Completion

Jun 30, 2027

Study Design

Enrollment

101 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Oral tranexamic acid
• No Intervention: Control Group

Primary Outcome Measure

Visual Analog Score [ Time Frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks ]

Locations (1)

Find similar trials in Scottsdale, AZ

Related Studies

• INHANCE Stemless Reverse Shoulder IDE
  Recruiting · DePuy Orthopaedics · Los Angeles, California